fashion -WSS

fashion

author：fashion 2025-10-01 11:34:13 - browse：4

Anthony Fernandez holds a Wegovy injection, the ALP-1 agonist medication he uses to help curb his food cravings – Obesity medication and science coverage for STAT — A person holds a Wegovy injection pen. Kayana Szymczak for STAT

Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.

Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Medicare would start covering the drug for this usage.

Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Diagnostic tests are hitting their mathematical limits

entertainment

WSS

Pediatric cancer treatments threatened by a new FDA policy

Addressing health care workers' trauma can help fight burnout

With clinical trial data readouts, here's how to spot spin

Mayo Clinic plans $5B tech

ASCO eve: Let’s set the table for this year's meeting

Bird flu surveillance in wastewater gets boost from consortium

hotspot

fashion

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Diagnostic tests are hitting their mathematical limits

BioMarin wins approval for gene therapy to treat hemophilia A

Flagship Pioneering launches a new biotech in two countries

Dobbs anniversary: the lost opportunity of abortion as health care

Reports of telehealth's death have been greatly exaggerated

Cancer drug shortages should be causing more outrage

UnitedHealth argues against case alleging wrongful AI care denials

Medical records are filled with copy

Addressing health care workers' trauma can help fight burnout

focus

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Biogen joins immunology wave with $1.15 billion acquisition of HI

Takeda, Janssen join wearable maker to measure scratching

Takeda, Janssen join wearable maker to measure scratching

BIO selects John Crowley as new CEO

How to pay for weight loss drugs and save Medicare

hotspot

entertainment

Wikipedia

leisure time